The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S. Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo) for the treatment of adult and...
More endometrial cancer patients can now receive an immunotherapy, and taking aspirin regularly may help some people reduce their risk for colorectal cancer.
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo) for the treatment of adult and pediatric...
Blood test approval widens access to colorectal cancer screening option, and language barriers interrupt cancer care before it starts.
Afamitresgene autoleucel has received accelerated approval to treat certain patients with synovial sarcoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to afamitresgene autoleucel (Tecelra, afami-cel) for the treatment of certain...
The FDA has approved dostarlimab-gxly plus chemotherapy to treat more patients with endometrial cancer. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) in combination with the chemotherapies carboplatin and paclitaxel, followed...
The targeted therapy was approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone. The U.S. Food and Drug Administration (FDA) has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro), plus bortezomib, lenalidomide,...
New cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening and monitoring.
Double mastectomy doesn’t lead to a survival advantage over lumpectomy or single mastectomy, and research explores hearing loss linked to cisplatin.
Clinical trials for dogs with cancer can extend the lives of our four-legged friends while revealing insights about cancer in humans.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More